Curis expands TakeAim Leukemia study to 30 patients; 6/11 FLT3m and 4/18 SFm respond

CURIS INC

TakeAim Leukemia dataset expanded from 5 to 30 R/R AML patients (25 new) with emavusertib monotherapy at 300 mg BID.
FLT3m cohort: 6/11 evaluable patients achieved objective response (3 CR, 1 CRh, 2 MLFS); responses mostly in one cycle.
SFm cohort: 4/18 evaluable patients achieved objective response (1 CR, 2 CRh, 1 MLFS); 3 additional patients showed increased neutrophils.
All responders had complete bone marrow blast normalization; two patients proceeded to allogenic stem cell transplant.
Curis discloses insufficient cash to fund operations for next 12 months, highlighting need for additional capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.